Monoclonal antibody WM-25 inhibited the in vitro growth of 13 F38 isolates from goats with contagious caprine pleuropneumonia but not 7 heterologous mycoplasma isolates representing four different species. In contrast to results with polyclonal antisera, growth inhibition by monoclonal antibody WM-25 was specific for F38 mycoplasma isolates and constituted a reliable means of distinguishing F38 from other mycoplasmas.
Contagious caprine pleuropneumonia (CCPP) is a disease of major economic importance in Asia and Africa, posing a major constraint to goat production because of high mortalities. The disease occurs in 33 countries; 8 others are on a suspect list (2) . Mycoplasma F38, isolated from a goat with pleuropneumonia in Kenya (16) , produces classical CCPP, which includes transmission by contact, high mortality, and a fibrinous pleuropneumonia characterized by massive hepatization and pleurisy. Similar mycoplasmas are isolated from goats in Sudan (11) and Yemen (J. K. Bari, M.S. thesis, Washington State University, Pullman, 1984). There is a need to establish whether F38 causes the CCPP reported in other countries (2) .
Initial studies of F38 from Kenya suggested it might represent a new mycoplasma species (7). Also, electrophoretic analysis showed that F38 had isoenzyme patterns distinct from those of other mycoplasmas (22) . However, in serological tests, F38 cross-reacts with several already established mycoplasma species (6-8, 13, 14) . Further work using DNA hybridization (3) and two-dimensional electrophoresis of cell proteins (1, 19) did not clearly distinguish F38 from other mycoplasmas isolated from goats. Growth inhibition (4) and indirect epiimmunofluorescence (5) assays are considered species specific and are used to classify mycoplasma isolates (9) . In these later tests, F38 crossreacts with two other mycoplasmas which do not cause CCPP, bovine serogroup 7 and Mycoplasma capricolum (14, 15 (14) . Polyclonal antiserum to each of the seven mycoplasmas caused growth inhibition of the homologous mycoplasma. (14) . Differences in the polyclonal antiserum could explain why this later cross-reaction by growth inhibition with polyclonal antisera was not seen in this study.
The mechanisms by which antibody inhibits the growth of mycoplasmas are not clearly understood. The fact that monoclonal antibody WM-25 did not inhibit the growth of heterologous mycoplasmas would suggest that these mycoplasma species do not possess the epitope recognized by WM-25 or that, if they do, the epitope either is not exposed on the live mycoplasma or has changed to the extent that WM-25 binding does not inhibit growth.
In conclusion, monoclonal antibody WM-25 caused growth inhibition of 13 F38 mycoplasma isolates and did not inhibit 7 other mycoplasma species. Use of WM-25 in growth inhibition resolved the only cross-reaction observed in this study, i.e., cross-growth inhibition of F38 and bovine serogroup 7 with polyclonal antisera. These data suggest that growth inhibition by WM-25 could be used to identify and classify F38 mycoplasmas.
